Most life sciences companies may know more about their healthcare professionals (HCPs) than they realize, but too often they can’t use that data when it matters. For example, an HCP may have just attended a conference where a competitor showcased their drug’s promising results, published research, and shifted their prescriptions to a rival product in the past quarter. In most companies, legacy IT infrastructure and data silos keep this information in disparate systems across CRM, events
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Opentrons and NVIDIA Partner to Develop Physical AI for Laboratory Robotics
What You Should Know
The Partnership: Opentrons Labworks, the company behind the ubiquitous pipette robots found in labs worldwide, is partnering with NVIDIA to accelerate the development of "Physical AI."The Integration: By combining NVIDIA's Isaac and Cosmos platforms with Opentrons' fleet of 10,000+ robots, the companies aim to create a "closed loop" where AI doesn't just predict drug targets (via NVIDIA BioNeMo) but physically validates them in the wet lab.The Goal: The collaboration
Read More
From Mass Messaging to N-of-1: How Agentic AI Closes the Life Sciences Trust Gap
What You Should Know
The Failure: Lirio, in partnership with healthcare consultancy Sage Growth Partners, released "From Mass Messaging to N-of-1," a survey of 75 life sciences executives. The report reveals that traditional "segment-based" personalization in life sciences is failing to move the needle. 79% of leaders cite clinical trial engagement and 72% cite medication adherence as their most persistent challenges.The Shift: The industry is pivoting from "Mass Messaging" to "N-of-1"
Read More
Why Pharma Marketing’s “Safe” Playbook Is Expiring in 2026
Pharma marketing has always operated within strict regulatory boundaries. What’s changing as we head into 2026 is not just the level of scrutiny, but the pace and unpredictability of it. Platform policies, data usage rules, targeting limitations, and compliance standards are evolving unevenly across channels and often without much warning.
That volatility is forcing pharma marketers to rethink how they plan, buy, and optimize media. The old playbook which was built around a
Read More
ConcertAI Bets “Agentic AI” Can Fix the Broken Clinical Trial Timeline
What You Should Know
The Launch: ConcertAI has released Accelerated Clinical Trials (ACT), an enterprise platform designed to automate the clinical trial lifecycle using "Agentic AI"—autonomous software that performs tasks rather than just generating text.The Promise: By integrating proprietary Real-World Data (RWD) with AI workflows, the platform claims it can shorten trial timelines by 10 to 20 months and reduce costly protocol amendments by 50%.The Tech: Built on the CARAai™
Read More
Medable Deploys ”Agentic AI” to Rescue Overwhelmed Investigators
What You Should Know:
- Medable Inc., the leading technology platform for AI-powered clinical development, today launched Agentic AI for research sites to reduce burden and assist principal investigators (PIs) in oversight and monitoring of electronic clinical outcome assessment (eCOA) data.
- Medable’s newest agent integrates seamlessly within its eCOA system workflows. Released just after Medable’s TMF and CRA agents, its PI Summary Agent continues the company’s rapid rollout of
Read More
Oracle Launches AI Platform to End the “Data Silo” Era in Pharma
What You Should Know
The Launch: Oracle has unveiled the Oracle Life Sciences AI Data Platform, a generative AI solution designed to unify the fragmented data ecosystems of pharmaceutical and medical device companies.The Asset: The platform doesn't just process customer data; it comes pre-loaded with access to 129 million+ de-identified real-world data records from Oracle Health, providing a massive baseline for analysis.The Tech: Beyond standard LLMs, the platform uses "Agentic Reasoning."
Read More
Biology: Cellares Raises $257M to Industrialize Cell Therapy
What You Should Know
The News: Cellares has raised $257M in Series D financing, bringing its total capital to $612 million. The round was co-led by BlackRock and Eclipse.The Tech: Cellares is building the world's first IDMO (Integrated Development and Manufacturing Organization). Its Cell Shuttle™ and Cell Q™ platforms fully automate the manufacturing and quality control of cell therapies, replacing "artisanal" manual processes.The Scale: The company claims its automated "Smart Factories" can
Read More
The End of the Guessing Game: Why Primary Care is Finally Ready for Pharmacogenomics
Pharmacogenomics, also referred to as PGx, is the use of a patient’s genetic makeup to guide safer, more effective medication choices and dosing in everyday clinical practice, including primary care. Although it has emerged as an essential and evidence-based tool in the primary care toolbox, its widespread adoption remains slow.
After more than 30 years in family medicine, I’ve watched every major clinical innovation face early skepticism – from electronic medical records to laparoscopic and
Read More
How Crossroads Health Ventures’ $21M Fund Accelerates Indiana Life Sciences
What You Should Know
The News: Crossroads Health Ventures (CHV) has launched a new early-stage venture fund with over $21M in capital to support Indiana-based life sciences startups.The Backers: The fund represents a rare collaboration between the state (IEDC), academia (Indiana University), and three global industry leaders: Eli Lilly (human health), Elanco (animal health), and Corteva (plant health).The Strategy: CHV aims to bridge the early-stage funding gap for companies operating
Read More
